Flamingo Therapeutics, Inc., a biotechnology company pioneering RNA-targeting therapies in oncology, today announced that it has entered into an agreement with Ionis Pharmaceuticals to develop RNA-targeted therapies to treat various forms of cancer. This alliance is an expansion of an existing collaboration with Ionis on the FLAME™ discovery engine, following Flamingo's Series A financing in 2020.
As the biggest name in antisense technology, Ionis has long focused on testing the interplay between oligonucleotides and RNA for therapeutic effect. But one class of RNA has mostly stumped researchers — until now.nFlamingo Therapeutics officially debuted Thursday with three clinical and one preclinical cancer drugs handed off from antisense guru Ionis, and an intriguing if unproven discovery engine gunning for mysterious long non-coding RNA targets.
Crescent Pharma Ltd and Flamingo Pharma (UK) Ltd have informed us that the Patient Information Leaflet (PIL) within their packs for the above pharmacy (P) batches is incorrect.
Flamingo Pharms Generic Piroxicam Approved In US
Flamingo Pharm`s Generic Metronidazole approved in US to treat bacterial infections